1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Glutaminase

Glutaminase (谷氨酰胺酶)

Glutaminase is the initial enzyme in glutamine metabolism, which catalyzes the hydrolysis of glutamine to glutamate in cells. Glutaminase plays a key role in cancer cell metabolism, growth, and proliferation. In mammalian cells, there are two paralogous GLS genes, GLS1 (or GLS) and GLS2. GLS1 encodes two alternatively spliced isozymes: kidney glutaminase (KGA) and glutaminase C (GAC). GLS2 also encodes two isozymes: liver glutaminase (LGA) and glutaminase B.

GLS1 is ubiquitously expressed in various tissues, and its expression can be induced by the oncogene MYC. GLS1 is frequently activated and/or overexpressed in various types of cancer, including hepatocellular carcinoma (HCC). GLS1 has been reported to promote tumorigenesis in different types of cancer, including HCC, which is mainly attributable to its glutaminase activity and role in promoting glutamine metabolism. GLS has emerged as a critical enzyme in a number of cancer types. Elevated GLS2 enzymatic activity has also been correlated with tumor cell growth in vitro and in vivo. N-Myc activates GLS2 to promote conversion of glutamine to glutamate in MYCN-amplified neuroblastoma cells. Abrogation of GLS2 function profoundly inhibits glutaminolysis and dramatically decreases cell proliferation and survival in vitro and in vivo. However, there is controversy over the role of GLS2 as a tumor suppressor. Enzymatic activity independent of GLS2 is up-regulated via p53 or p63 and plays a role of tumor suppressor.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12248
    Telaglenastat Inhibitor 99.82%
    Telaglenastat (CB-839) 是一种首创的,选择性的,可逆性的,口服活性的谷氨酰胺酶 1 (GLS1) 抑制剂。Telaglenastat 抑制 GLS1 剪接变异体 KGAGAC,比 GLS2 具有更高的选择性。Telaglenastat 对小鼠类肾和脑中的内源性谷氨酰胺酶的 IC50 值分别为 23 nM 和 28 nM。Telaglenastat 还可诱导细胞自噬 (autophagy),并具有强大的抗肿瘤活性。
    Telaglenastat
  • HY-12683
    BPTES Inhibitor 98.98%
    BPTES是选择性的谷氨酰胺酶变构抑制剂,IC50 为0.16 μM。
    BPTES
  • HY-108357
    6-Diazo-5-oxo-L-nor-Leucine

    6-重氮-5-氧代-L-正亮氨酸

    Antagonist 99.98%
    6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) 是一种谷氨酰胺拮抗剂,能不可逆地抑制谷氨酰胺的分解作用。6-Diazo-5-oxo-L-nor-Leucine 具有较好的抗癌活性 (尤其是胰腺癌),能降低肿瘤细胞的自我更新潜力和转移能力。6-Diazo-5-oxo-L-nor-Leucine 还具有抗菌和抗病毒活性。
    6-Diazo-5-oxo-L-nor-Leucine
  • HY-122218
    JHU-083 Antagonist ≥98.0%
    JHU-083 是 6-diazo-5-oxo-L-norleucine (DON; HY-108357) 的前体,是一种口服有效的,选择性的谷氨酰胺酶 (glutaminase) 拮抗剂,可阻断脑 CD11b+ 细胞和实验性脑疟疾 (ECM) 中的谷氨酰胺酶,导致动物中谷氨酸水平的净降低。
    JHU-083
  • HY-B1692
    L-Methionine-DL-sulfoximine Inhibitor ≥98.0%
    L-Methionine-DL-sulfoximine (MSX; MSO),一种 Glutamine synthetase 的高度特异性和不可逆抑制剂,也是一种有效的惊厥药,在代谢和形态上主要影响星形胶质细胞。L-Methionine-DL-sulfoximine 已被用于抑制体外谷氨酰胺依赖的氨刺激的神经元毒性,增强谷氨酰胺缺陷依赖的抑郁症。L-Methionine-DL-sulfoximine 极大地增加了蓝藻中固定氮的释放速度。L-Methionine-DL-sulfoximine 有望用于生物肥料和惊厥发作的研究。
    L-Methionine-DL-sulfoximine
  • HY-136704
    GLS1 Inhibitor-1 Inhibitor
    GLS1 Inhibitor-1 (Compound 27) 是口服有效的谷氨酰胺酶 1 (glutaminase 1GLS1) 抑制剂,IC50 为 0.021 μM。GLS1 Inhibitor-1 可抑制 PC-3 的增殖,IC50 为 0.3 nM。GLS1 Inhibitor-1 对 NCI-H1703 具有抗肿瘤作用,GI50 为 0.011 μM。GLS1 Inhibitor-1 具有适中的药代动力学特性。
    GLS1 Inhibitor-1
  • HY-158378
    Trivalent hydroxyarsinothricn Inhibitor
    Trivalent hydroxyarsinothricn (R-AST-OH) 是一种共价且不可逆的肾型谷氨酰胺酶 (KGA)抑制剂。Trivalent hydroxyarsinothricn 与谷氨酰胺结合位点结合,并与活性位点半胱氨酸残基形成共价键。Trivalent hydroxyarsinothricn 选择性杀死三阴性乳腺癌 (TNBC) 细胞,且对照细胞系无细胞毒性。KGA 是控制谷氨酰胺代谢的酶,与肿瘤恶性程度相关。
    Trivalent hydroxyarsinothricn
  • HY-125958
    AA9 Inhibitor
    AA9 是一种有效的 Transglutaminase 2 (TG2) 抑制剂。AA9 对 HIF 介导的 MDA-MB-231 细胞缺氧有较强的影响。
    AA9
  • HY-12682
    Glutaminase C-IN-1 Inhibitor 99.88%
    Glutaminase C-IN-1 (Compound 968) 是 Glutaminase C 变构抑制剂,可抑制癌细胞生长而不影响其正常细胞对应体。
    Glutaminase C-IN-1
  • HY-19359
    ZED-1227 Inhibitor 99.97%
    ZED-1227 是一种特异性的,具有口服活性的转谷氨酰胺酶 2 (TG2) 抑制剂,IC50值为 45 nM。ZED-1227 能阻塞炎症诱导的 TG2 表达和激活,可用于乳糜泻的研究。
    ZED-1227
  • HY-W015309
    Decanoic acid

    癸酸

    Inhibitor ≥98.0%
    Decanoic acid 是椰子油中发现的中链甘油三酯 (MCT) 的关键成分。Decanoic acid 是一种具有脑渗透和非竞争性的 AMPA 受体抑制剂,在大鼠中具有抗癫痫活性。Decanoic acid 降低 tyrosinase 活性,抑制 melanosome 成熟。Decanoic acid 通过抑制多种致癌蛋白的表达,抑制肝癌细胞 c-Met 的磷酸化,诱导细胞凋亡,有望用于在 mTORC1 信号通路、肝癌和癫痫等领域的研究。
    Decanoic acid
  • HY-12337
    GK921 Inhibitor 99.93%
    GK921是转谷氨酰胺酶2 (TGase2) 抑制剂,对人类重组TGase2的IC50值为7.71 μM。
    GK921
  • HY-W020050
    Cystamine dihydrochloride Inhibitor ≥98.0%
    Cystamine (dihydrochloride) 是游离硫醇半胱胺的二硫化物形式。Cystamine 是一种转谷氨酰胺酶 (Tgase) 抑制剂,具有口服活性。Cystamine 对 caspase-3 也有抑制活性,IC50 值为 23.6 μM。Cystamine 可用于亨廷顿舞蹈病(HD)等多种疾病的研究。
    Cystamine dihydrochloride
  • HY-124476
    Cystamine Inhibitor 99.79%
    Cystamine 是游离硫醇半胱胺的二硫化物形式。Cystamine 是一种转谷氨酰胺酶 (Tgase) 抑制剂,具有口服活性。Cystamine 对 caspase-3 也有抑制活性,IC50 值为 23.6 μM。Cystamine 可用于亨廷顿舞蹈病(HD)等多种疾病的研究。
    Cystamine
  • HY-123290
    KCC009 Inhibitor 98.06%
    KCC009 是转谷氨酰胺酶 2 的抑制剂,可诱导 p53 途径依赖的放疗敏感性。
    KCC009
  • HY-117678
    TG-2-IN-1 Inhibitor ≥98.0%
    TG-2-IN-1 (Compound D003) 是一种转谷氨酰胺酶-2 (TGM-2) 抑制剂。TG-2-IN-1 可用于近视研究。
    TG-2-IN-1
  • HY-114334
    Glutaminase-IN-1 Inhibitor 98.09%
    Glutaminase-IN-1 (CB839 derivative) 是CB839 的一个衍生物,是1,3,4-硒二氮基肾型谷氨酰胺酶(KGA) 的变构抑制剂,其IC50 值为1 nM。Glutaminase-IN-1 (CB839 derivative) 具有提高细胞摄取和抗肿瘤的活性。
    Glutaminase-IN-1
  • HY-103671
    IPN60090 Inhibitor 99.47%
    IPN-60090 是一种具有口服活性和高选择性的谷氨酰胺酶 1 GLS1 的抑制剂 (IC50=31 nM),对 GLS-2 无活性。IPN-60090 在体内表现出优良的物理化学和药代动力学特性。IPN-60090 可用于实体肿瘤的研究,如肺癌和卵巢癌。
    IPN60090
  • HY-121167
    L-Albizziin Inhibitor ≥98.0%
    L-albizziin 为一种巯基试剂,是谷氨酰胺酶抑制剂。L-albizziin 可用于癌症研究。
    L-Albizziin
  • HY-79583
    Glutaminase-IN-3 Inhibitor 98.47%
    Glutaminase-IN-3 (compound 657) 是一种有效的 glutaminase 抑制剂,对GLS1的 IC50 值为0.24 μM。详细情况请参见专利 WO2014089048A1,compound 657。
    Glutaminase-IN-3
目录号 产品名 / 同用名 应用 反应物种